{"pmid":32372695,"title":"Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol.","text":["Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol.","More than 2,000,000 individuals worldwide have had coronavirus 2019 disease infection (COVID-19), yet there is no effective medical therapy. Multiple off-label and investigational drugs, such as chloroquine and hydroxychloroquine, have gained broad interest due to positive pre-clinical data and are currently used for treatment of COVID-19. However, some of these medications have potential cardiac adverse effects. This is important because up to one-third of patients with COVID-19 have cardiac injury, which can further increase the risk of cardiomyopathy and arrhythmias. Adverse effects of chloroquine and hydroxychloroquine on cardiac function and conduction are broad and can be fatal. Both drugs have an anti-arrhythmic property and are proarrhythmic. The American Heart Association has listed chloroquine and hydroxychloroquine as agents which can cause direct myocardial toxicity. Similarly, other investigational drugs such as favipiravir and lopinavir/ritonavir can prolong QT interval and cause Torsade de Pointes. Many antibiotics commonly used for the treatment of patients with COVID-19, for instance azithromycin, can also prolong QT interval. This review summarizes evidenced-based data regarding potential cardiac adverse effects due to off-label and investigational drugs including chloroquine and hydroxychloroquine, antiviral therapy, monoclonal antibodies, as well as common antibiotics used for the treatment of COVID-19. The article focuses on practical points and offers a point-of-care protocol for providers who are taking care of patients with COVID-19 in an inpatient and outpatient setting. The proposed protocol is taking into consideration that resources during the pandemic are limited.","Eur Heart J Acute Cardiovasc Care","Naksuk, Niyada","Lazar, Sorin","Peeraphatdit, Thoetchai Bee","32372695"],"abstract":["More than 2,000,000 individuals worldwide have had coronavirus 2019 disease infection (COVID-19), yet there is no effective medical therapy. Multiple off-label and investigational drugs, such as chloroquine and hydroxychloroquine, have gained broad interest due to positive pre-clinical data and are currently used for treatment of COVID-19. However, some of these medications have potential cardiac adverse effects. This is important because up to one-third of patients with COVID-19 have cardiac injury, which can further increase the risk of cardiomyopathy and arrhythmias. Adverse effects of chloroquine and hydroxychloroquine on cardiac function and conduction are broad and can be fatal. Both drugs have an anti-arrhythmic property and are proarrhythmic. The American Heart Association has listed chloroquine and hydroxychloroquine as agents which can cause direct myocardial toxicity. Similarly, other investigational drugs such as favipiravir and lopinavir/ritonavir can prolong QT interval and cause Torsade de Pointes. Many antibiotics commonly used for the treatment of patients with COVID-19, for instance azithromycin, can also prolong QT interval. This review summarizes evidenced-based data regarding potential cardiac adverse effects due to off-label and investigational drugs including chloroquine and hydroxychloroquine, antiviral therapy, monoclonal antibodies, as well as common antibiotics used for the treatment of COVID-19. The article focuses on practical points and offers a point-of-care protocol for providers who are taking care of patients with COVID-19 in an inpatient and outpatient setting. The proposed protocol is taking into consideration that resources during the pandemic are limited."],"journal":"Eur Heart J Acute Cardiovasc Care","authors":["Naksuk, Niyada","Lazar, Sorin","Peeraphatdit, Thoetchai Bee"],"date":"2020-05-07T11:00:00Z","year":2020,"_id":"32372695","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1177/2048872620922784","keywords":["covid-19","adverse effects","arrhythmias","cardiac","drugs","treatment"],"e_drugs":["Hydroxychloroquine","Azithromycin","lopinavir-ritonavir drug combination","Chloroquine","favipiravir"],"topics":["Treatment"],"weight":1,"_version_":1666138496447807489,"score":9.490897,"similar":[{"pmid":32463308,"title":"Chloroquine or Hydroxychloroquine for COVID-19: Is Cardiotoxicity a Concern?","text":["Chloroquine or Hydroxychloroquine for COVID-19: Is Cardiotoxicity a Concern?","The SARS-Cov-2 viral pandemic causing COVID-19 disease begs for rapid and innovative treatments. In addition to flu-like respiratory symptoms, acute cardiac manifestations include cardiac injury, shock and arrhythmia. Several pharmacological therapies have been suggested including repurposing of existing drugs such as chloroquine and hydroxychloroquine, sometimes co-administered with azithromycin. Chloroquine and hydroxychloroquine were developed in the World War II era for treatment and prophylaxis of malaria, long before modern drug safety surveillance programs. Clinically they can prolong the QT interval to potentially initiate ventricular arrhythmias including torsades de pointes, and also cause QRS widening. Chloroquine interacts with multiple cardiac ion channels including the hERG potassium channel that is essential for normal electrical activity in the heart. A reduction in hERG channel potassium current is the principle cause of drug-induced long QT syndrome. Azithromycin also can cause modest QT interval prolongation, but not through potent hERG channel blockade, rather when used chronically through an increase in peak and late cardiac sodium current to cause potential loading of cardiomyocytes with sodium and calcium to produce calcium overload. How should we proceed with the use of chloroquine and hydroxychloroquine, potentially combined with azithromycin, for COVID-19 given that these agents bring some cardiac toxicity risk and their mechanisms for cardiac toxicity may not be the same? Is combining different and potentially additive mechanisms of cardiotoxicity wise? How great the risk is relative to the benefit in critically ill COVID-19 patients will need to await the outcome of ongoing, controlled clinical trials.","J Am Heart Assoc","Kamp, Timothy J","Hamdan, Mohamed H","January, Craig T","32463308"],"abstract":["The SARS-Cov-2 viral pandemic causing COVID-19 disease begs for rapid and innovative treatments. In addition to flu-like respiratory symptoms, acute cardiac manifestations include cardiac injury, shock and arrhythmia. Several pharmacological therapies have been suggested including repurposing of existing drugs such as chloroquine and hydroxychloroquine, sometimes co-administered with azithromycin. Chloroquine and hydroxychloroquine were developed in the World War II era for treatment and prophylaxis of malaria, long before modern drug safety surveillance programs. Clinically they can prolong the QT interval to potentially initiate ventricular arrhythmias including torsades de pointes, and also cause QRS widening. Chloroquine interacts with multiple cardiac ion channels including the hERG potassium channel that is essential for normal electrical activity in the heart. A reduction in hERG channel potassium current is the principle cause of drug-induced long QT syndrome. Azithromycin also can cause modest QT interval prolongation, but not through potent hERG channel blockade, rather when used chronically through an increase in peak and late cardiac sodium current to cause potential loading of cardiomyocytes with sodium and calcium to produce calcium overload. How should we proceed with the use of chloroquine and hydroxychloroquine, potentially combined with azithromycin, for COVID-19 given that these agents bring some cardiac toxicity risk and their mechanisms for cardiac toxicity may not be the same? Is combining different and potentially additive mechanisms of cardiotoxicity wise? How great the risk is relative to the benefit in critically ill COVID-19 patients will need to await the outcome of ongoing, controlled clinical trials."],"journal":"J Am Heart Assoc","authors":["Kamp, Timothy J","Hamdan, Mohamed H","January, Craig T"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32463308","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1161/JAHA.120.016887","keywords":["cardiotoxicity","drug therapy","long qt syndrome"],"locations":["Hydroxychloroquine"],"e_drugs":["Potassium","Sodium","Chloroquine","Hydroxychloroquine","Azithromycin","Calcium"],"topics":["Treatment"],"weight":1,"_version_":1668079521443610624,"score":395.79044},{"pmid":32438018,"title":"QT prolongation, torsades de pointes and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: a systematic review.","text":["QT prolongation, torsades de pointes and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: a systematic review.","Chloroquine and hydroxychloroquine are now being widely used as treatments for COVID-19. Both medications prolong the QT interval and accordingly may put patients at increased risk of torsades de pointes and sudden death. Published guidance documents vary in their recommendations for monitoring and managing these potential adverse effects. Accordingly, we set out to conduct a systematic review of the arrhythmogenic effect of short courses of chloroquine or hydroxychloroquine. We searched in MEDLINE and Embase, as well as grey literature up to April 17, 2020, on the risk of QT prolongation, torsades, ventricular arrhythmia, and sudden death with short-term chloroquine and hydroxychloroquine usage. This resulted in 390 unique records, of which fourteen were ultimately selected for qualitative synthesis and which included data on 1515 COVID-19 patients. Approximately 10% of COVID-19 patients treated with these drugs developed QT prolongation. We found evidence of ventricular arrhythmia in two COVID-19 patients out of a group of 28 treated with high-dose chloroquine. A limitation of these results is unclear follow-up and possible publication/reporting bias, but there is compelling evidence that chloroquine and hydroxychloroquine induce significant QT interval prolongation and potentially increase the risk of arrhythmia. Daily ECG monitoring and other risk mitigation strategies should be considered in order to prevent possible harms from what is currently an unproven therapy.","Heart Rhythm","Jankelson, Lior","Karam, Giorgio","Becker, Matthijs L","Chinitz, Larry A","Tsai, Meng-Chiao","32438018"],"abstract":["Chloroquine and hydroxychloroquine are now being widely used as treatments for COVID-19. Both medications prolong the QT interval and accordingly may put patients at increased risk of torsades de pointes and sudden death. Published guidance documents vary in their recommendations for monitoring and managing these potential adverse effects. Accordingly, we set out to conduct a systematic review of the arrhythmogenic effect of short courses of chloroquine or hydroxychloroquine. We searched in MEDLINE and Embase, as well as grey literature up to April 17, 2020, on the risk of QT prolongation, torsades, ventricular arrhythmia, and sudden death with short-term chloroquine and hydroxychloroquine usage. This resulted in 390 unique records, of which fourteen were ultimately selected for qualitative synthesis and which included data on 1515 COVID-19 patients. Approximately 10% of COVID-19 patients treated with these drugs developed QT prolongation. We found evidence of ventricular arrhythmia in two COVID-19 patients out of a group of 28 treated with high-dose chloroquine. A limitation of these results is unclear follow-up and possible publication/reporting bias, but there is compelling evidence that chloroquine and hydroxychloroquine induce significant QT interval prolongation and potentially increase the risk of arrhythmia. Daily ECG monitoring and other risk mitigation strategies should be considered in order to prevent possible harms from what is currently an unproven therapy."],"journal":"Heart Rhythm","authors":["Jankelson, Lior","Karam, Giorgio","Becker, Matthijs L","Chinitz, Larry A","Tsai, Meng-Chiao"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32438018","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.hrthm.2020.05.008","keywords":["covid-19","sars-cov-2","arrhythmia","chloroquine","coronavirus","hydroxychloroquine","sudden death","torsades de pointes"],"e_drugs":["Chloroquine","Hydroxychloroquine"],"topics":["Treatment"],"weight":1,"_version_":1667521393823055872,"score":359.20035},{"pmid":32418730,"title":"\"Off-label\" use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers.","text":["\"Off-label\" use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers.","INTRODUCTION: COVID-19 is an unprecedented challenge for physicians and scientists. Several publicized drugs are being used with not much evidence of their efficacy such as hydroxychloroquine, azithromycin or lopinavir-ritonavir. Yet, the cardiac safety of these drugs in COVID-19 deserves scrutiny as they are known to foster cardiac adverse ADRs, notably QTc interval prolongation on the electrocardiogram and its arrhythmogenic consequences. METHODS: Since March 27th, 2020, the French Pharmacovigilance Network directed all cardiac adverse drug reactions associated with \"off-label\" use of hydroxychloroquine, azithromycin and lopinavir-ritonavir in COVID-19 to the Nice Regional Center of Pharmacovigilance. Each Regional Center of Pharmacovigilance first assessed causality of drugs. We performed a specific analysis of these cardiac adverse drug reactions amidst an array of risk factors, reassessed the electrocardiograms and estimated their incidence in coronavirus disease 2019. RESULTS: In one month, 120 reports of cardiac adverse drug reactions have been notified, 103 of which associated with hydroxychloroquine alone (86%), or associated with azithromycin (60%). Their estimated incidence is 0.77% to 1.54% of all patients, notwithstanding strong underreporting. Lopinavir-ritonavir came third with 17 reports (14%) and chloroquine fourth with 3 reports (2.5%). There were 8 sudden, unexplained or aborted deaths (7%), 8 ventricular arrhythmias (7%), 90 reports of prolonged QTc (75%) most of them \"serious\" (64%), 48 of which proved >/= 500ms, 20 reports of severe conduction disorders (17%) and 5 reports of other cardiac causes (4%). Six reports derived from automedication. DISCUSSION AND CONCLUSION: \"Off-label\" use of treatments in COVID-19 increases the risk of cardiac ADRs, some of them avoidable. Even if these drugs are perceived as familiar, they are used in patients with added risk factors caused by infection. Precautions should be taken to mitigate the risk, even if they will be proven efficacious.","Therapie","Gerard, Alexandre","Romani, Serena","Fresse, Audrey","Viard, Delphine","Parassol, Nadege","Granvuillemin, Aurelie","Chouchana, Laurent","Rocher, Fanny","Drici, Milou-Daniel","32418730"],"abstract":["INTRODUCTION: COVID-19 is an unprecedented challenge for physicians and scientists. Several publicized drugs are being used with not much evidence of their efficacy such as hydroxychloroquine, azithromycin or lopinavir-ritonavir. Yet, the cardiac safety of these drugs in COVID-19 deserves scrutiny as they are known to foster cardiac adverse ADRs, notably QTc interval prolongation on the electrocardiogram and its arrhythmogenic consequences. METHODS: Since March 27th, 2020, the French Pharmacovigilance Network directed all cardiac adverse drug reactions associated with \"off-label\" use of hydroxychloroquine, azithromycin and lopinavir-ritonavir in COVID-19 to the Nice Regional Center of Pharmacovigilance. Each Regional Center of Pharmacovigilance first assessed causality of drugs. We performed a specific analysis of these cardiac adverse drug reactions amidst an array of risk factors, reassessed the electrocardiograms and estimated their incidence in coronavirus disease 2019. RESULTS: In one month, 120 reports of cardiac adverse drug reactions have been notified, 103 of which associated with hydroxychloroquine alone (86%), or associated with azithromycin (60%). Their estimated incidence is 0.77% to 1.54% of all patients, notwithstanding strong underreporting. Lopinavir-ritonavir came third with 17 reports (14%) and chloroquine fourth with 3 reports (2.5%). There were 8 sudden, unexplained or aborted deaths (7%), 8 ventricular arrhythmias (7%), 90 reports of prolonged QTc (75%) most of them \"serious\" (64%), 48 of which proved >/= 500ms, 20 reports of severe conduction disorders (17%) and 5 reports of other cardiac causes (4%). Six reports derived from automedication. DISCUSSION AND CONCLUSION: \"Off-label\" use of treatments in COVID-19 increases the risk of cardiac ADRs, some of them avoidable. Even if these drugs are perceived as familiar, they are used in patients with added risk factors caused by infection. Precautions should be taken to mitigate the risk, even if they will be proven efficacious."],"journal":"Therapie","authors":["Gerard, Alexandre","Romani, Serena","Fresse, Audrey","Viard, Delphine","Parassol, Nadege","Granvuillemin, Aurelie","Chouchana, Laurent","Rocher, Fanny","Drici, Milou-Daniel"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32418730","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.therap.2020.05.002","keywords":["arrhythmia","azithromycin","covid-19","cardiac adverse effects","hydroxychloroquine","lopinavir","qtc prolongation"],"locations":["French"],"countries":["France"],"countries_codes":["FRA|France"],"e_drugs":["lopinavir-ritonavir drug combination","Hydroxychloroquine","Azithromycin","Chloroquine"],"topics":["Treatment"],"weight":1,"_version_":1667159284433027072,"score":354.6087},{"pmid":32347743,"title":"The Effect of Chloroquine, Hydroxychloroquine and Azithromycin on the Corrected QT Interval in Patients with SARS-CoV-2 Infection.","text":["The Effect of Chloroquine, Hydroxychloroquine and Azithromycin on the Corrected QT Interval in Patients with SARS-CoV-2 Infection.","Background - The novel SARs-CoV-2 coronavirus is responsible for the global COVID-19 pandemic. Small studies have shown a potential benefit of chloroquine/hydroxychloroquine +/- azithromycin for the treatment of COVID-19. Use of these medications alone, or in combination, can lead to a prolongation of the QT interval, possibly increasing the risk of Torsade de pointes (TdP) and sudden cardiac death. Methods - Hospitalized patients treated with chloroquine/hydroxychloroquine +/- azithromycin from March 1st through the 23rd at three hospitals within the Northwell Health system were included in this prospective, observational study. Serial assessments of the QT interval were performed. The primary outcome was QT prolongation resulting in TdP. Secondary outcomes included QT prolongation, the need to prematurely discontinue any of the medications due to QT prolongation and arrhythmogenic death. Results - Two hundred one patients were treated for COVID-19 with chloroquine/hydroxychloroquine. Ten patients (5.0%) received chloroquine, 191 (95.0%) received hydroxychloroquine and 119 (59.2%) also received azithromycin. The primary outcome of TdP was not observed in the entire population. Baseline QTc intervals did not differ between patients treated with chloroquine/hydroxychloroquine (monotherapy group) vs. those treated with combination group (chloroquine/hydroxychloroquine and azithromycin) (440.6 +/- 24.9 ms vs. 439.9 +/- 24.7 ms, p =0.834). The maximum QTc during treatment was significantly longer in the combination group vs the monotherapy group (470.4 +/- 45.0 ms vs. 453.3 +/- 37.0 ms, p = 0.004). Seven patients (3.5%) required discontinuation of these medications due to QTc prolongation. No arrhythmogenic deaths were reported. Conclusions - In the largest reported cohort of COVID-19 patients to date treated with chloroquine/hydroxychloroquine {plus minus} azithromycin, no instances of TdP or arrhythmogenic death were reported. Although use of these medications resulted in QT prolongation, clinicians seldomly needed to discontinue therapy. Further study of the need for QT interval monitoring is needed before final recommendations can be made.","Circ Arrhythm Electrophysiol","Saleh, Moussa","Gabriels, James","Chang, David","Kim, Beom Soo","Mansoor, Amtul","Mahmood, Eitezaz","Makker, Parth","Ismail, Haisam","Goldner, Bruce","Willner, Jonathan","Beldner, Stuart","Mitra, Raman","John, Roy","Chinitz, Jason","Skipitaris, Nicholas","Mountantonakis, Stavros","Epstein, Laurence M","32347743"],"abstract":["Background - The novel SARs-CoV-2 coronavirus is responsible for the global COVID-19 pandemic. Small studies have shown a potential benefit of chloroquine/hydroxychloroquine +/- azithromycin for the treatment of COVID-19. Use of these medications alone, or in combination, can lead to a prolongation of the QT interval, possibly increasing the risk of Torsade de pointes (TdP) and sudden cardiac death. Methods - Hospitalized patients treated with chloroquine/hydroxychloroquine +/- azithromycin from March 1st through the 23rd at three hospitals within the Northwell Health system were included in this prospective, observational study. Serial assessments of the QT interval were performed. The primary outcome was QT prolongation resulting in TdP. Secondary outcomes included QT prolongation, the need to prematurely discontinue any of the medications due to QT prolongation and arrhythmogenic death. Results - Two hundred one patients were treated for COVID-19 with chloroquine/hydroxychloroquine. Ten patients (5.0%) received chloroquine, 191 (95.0%) received hydroxychloroquine and 119 (59.2%) also received azithromycin. The primary outcome of TdP was not observed in the entire population. Baseline QTc intervals did not differ between patients treated with chloroquine/hydroxychloroquine (monotherapy group) vs. those treated with combination group (chloroquine/hydroxychloroquine and azithromycin) (440.6 +/- 24.9 ms vs. 439.9 +/- 24.7 ms, p =0.834). The maximum QTc during treatment was significantly longer in the combination group vs the monotherapy group (470.4 +/- 45.0 ms vs. 453.3 +/- 37.0 ms, p = 0.004). Seven patients (3.5%) required discontinuation of these medications due to QTc prolongation. No arrhythmogenic deaths were reported. Conclusions - In the largest reported cohort of COVID-19 patients to date treated with chloroquine/hydroxychloroquine {plus minus} azithromycin, no instances of TdP or arrhythmogenic death were reported. Although use of these medications resulted in QT prolongation, clinicians seldomly needed to discontinue therapy. Further study of the need for QT interval monitoring is needed before final recommendations can be made."],"journal":"Circ Arrhythm Electrophysiol","authors":["Saleh, Moussa","Gabriels, James","Chang, David","Kim, Beom Soo","Mansoor, Amtul","Mahmood, Eitezaz","Makker, Parth","Ismail, Haisam","Goldner, Bruce","Willner, Jonathan","Beldner, Stuart","Mitra, Raman","John, Roy","Chinitz, Jason","Skipitaris, Nicholas","Mountantonakis, Stavros","Epstein, Laurence M"],"date":"2020-04-30T11:00:00Z","year":2020,"_id":"32347743","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1161/CIRCEP.120.008662","keywords":["azithromycin","covid-19","chloroquine","hydroxychloroquine","pandemic"],"e_drugs":["Hydroxychloroquine","Chloroquine","Azithromycin"],"topics":["Treatment"],"weight":1,"_version_":1666138495397134337,"score":351.20746},{"pmid":32479900,"title":"Fatal arrhythmias: Another reason why doctors remain cautious about chloroquine/hydroxychloroquine for treating COVID-19.","text":["Fatal arrhythmias: Another reason why doctors remain cautious about chloroquine/hydroxychloroquine for treating COVID-19.","BACKGROUND: Early during the current COVID-19 pandemic, hydroxychloroquine (HCQ) received a significant amount of attention as a potential antiviral treatment, such that it became one of the most commonly prescribed medications for COVID-19 patients. However, not only the effectiveness of HCQ has remained questionable, and mainly based on pre-clinical, and a few small clinical studies, but also HCQ is known to be potentially arrhythmogenic, especially as a result of QT prolongation. OBJECTIVE: To investigate the arrhythmic effects of HCQ as the heightened risk is especially relevant as COVID-19 patients are at a higher risk of cardiac complications and arrhythmias at baseline. METHODS: Here, we use the optical mapping technique, using voltage-sensitive fluorescent dyes, to illustrate the arrhythmic effects of hydroxychloroquine in ex-vivo guinea pig and rabbit hearts perfused with the upper therapeutic serum doses of HCQ (up to 1000ng/ml). RESULTS: We observe that HCQ markedly increases the action potential dispersion and results in the development of repolarization alternans and initiate polymorphic ventricular tachycardia. CONCLUSIONS: These results further highlight the proarrhythmic effects of HCQ.","Heart Rhythm","Uzelac, Ilija","Iravanian, Shahriar","Ashikaga, Hiroshi","Bhatia, Neal K","Herndon, Conner","Kaboudian, Abouzar","Gumbart, James C","Cherry, Elizabeth M","Fenton, Flavio H","32479900"],"abstract":["BACKGROUND: Early during the current COVID-19 pandemic, hydroxychloroquine (HCQ) received a significant amount of attention as a potential antiviral treatment, such that it became one of the most commonly prescribed medications for COVID-19 patients. However, not only the effectiveness of HCQ has remained questionable, and mainly based on pre-clinical, and a few small clinical studies, but also HCQ is known to be potentially arrhythmogenic, especially as a result of QT prolongation. OBJECTIVE: To investigate the arrhythmic effects of HCQ as the heightened risk is especially relevant as COVID-19 patients are at a higher risk of cardiac complications and arrhythmias at baseline. METHODS: Here, we use the optical mapping technique, using voltage-sensitive fluorescent dyes, to illustrate the arrhythmic effects of hydroxychloroquine in ex-vivo guinea pig and rabbit hearts perfused with the upper therapeutic serum doses of HCQ (up to 1000ng/ml). RESULTS: We observe that HCQ markedly increases the action potential dispersion and results in the development of repolarization alternans and initiate polymorphic ventricular tachycardia. CONCLUSIONS: These results further highlight the proarrhythmic effects of HCQ."],"journal":"Heart Rhythm","authors":["Uzelac, Ilija","Iravanian, Shahriar","Ashikaga, Hiroshi","Bhatia, Neal K","Herndon, Conner","Kaboudian, Abouzar","Gumbart, James C","Cherry, Elizabeth M","Fenton, Flavio H"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32479900","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.hrthm.2020.05.030","keywords":["apd dispersion","arrhythmias","t wave alternans","alternans","experimental optical mapping","hydroxychloroquine","long qt"],"topics":["Treatment"],"weight":1,"_version_":1668437835026268160,"score":330.04428}]}